Key result
N-acetylcysteine plus deferoxamine decreased plasma markers of oxidative damage and creatinine levels at hospital discharge compared with placebo.
Why the study?
Does N-acetylcysteine and deferoxamine reduce oxidative damage and inflammation in critically ill patients with prolonged hypotension?
RCT (n=30)
Double-blind
randomized
Does N-acetylcysteine and deferoxamine reduce oxidative damage and inflammation in critically ill patients with prolonged hypotension?
In critically ill patients with prolonged hypotension, the combination of N-acetylcysteine and deferoxamine may reduce oxidative damage and improve renal function at hospital discharge.
No takes yet. Share an insight, caveat, or question.
May reduce oxidative damage and creatinine with NAC plus deferoxamine in hypotensive critically ill patients; extends prior antioxidant trials to this population.
Fraga et al. (2011) conducted an RCT in Prolonged hypotension in critical illness (n=30). N-acetylcysteine and deferoxamine vs. Placebo was evaluated on Serum levels of markers of oxidative damage and inflammatory response. N-acetylcysteine plus deferoxamine decreased plasma markers of oxidative damage and creatinine levels at hospital discharge compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: